Bio-Path Holdings, Inc. · OTC:BPTH

Bio-Path — Investor Presentation (May 2019)

23 slides from Bio-Path's investor presentation, May 2019

  1. Slide 1: Bio-Path Holdings: An Oncology-Focused Biotechnology Company

    Slide 1: Bio-Path Holdings: An Oncology-Focused Biotechnology Company

    Bio-Path Holdings An Oncology-Focused Biotechnology Company May 2019

  2. Slide 2: Forward looking statements

    Slide 2: Forward looking statements

    Forward looking statements This Presentation contains forward-looking statements with respect to business conducted by Bio-Path Holdings, Inc. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will

  3. Slide 3: Introducing Bio-Path Holdings

    Slide 3: Introducing Bio-Path Holdings

    Introducing Bio-Path Holdings Advanced Oligonucleotide Therapeutics with High Efficiency Systemic Delivery Publicly traded Employees Established NASDAQ 13 Houston, TX BPTH 2007 Technology Highlights ® DNAbilize Technology, next generation single-stranded DNA antisense Robust clinical pipeline with n

  4. Slide 4: Robust Oncology Pipeline

    Slide 4: Robust Oncology Pipeline

    Robust Oncology Pipeline Preclinical IND PHASE I PHASE II Prexigebersen (BP1001) AML* Prexigebersen (BP1001) CML* Prexigebersen (BP1001) Solid Tumors (ovarian, endometrial, pancreatic) *Orphan drug designation from the USFDA for AML and CML and from EMA for AML BP1002 (Liposomal Bcl2) Lymphoma, CLL

  5. Slide 5: DNAbilize Technology

    Slide 5: DNAbilize Technology

    DNAbilize Technology ® Proven As Safe, Robust and Targeted Method for Treating Disease No Toxicity No Toxicity With human patients to date in Prexigebersen clinical trial. • DNAbilize™ liposome structure is similar to the cellular membrane • P-ethoxy DNA does not induce hepatotoxicity or thrombocyto

  6. Slide 6: DNAbilize Technology: Nanoparticle Delivery Ensures Stabilization

    Slide 6: DNAbilize Technology: Nanoparticle Delivery Ensures Stabilization

    DNAbilize Technology ® Nanoparticle Delivery Ensures Stabilization • Lack of surface charge on lipid nanoparticle means avoidance of steric hindrance and ensures cellular uptake. • Slight hydrophobic nature allows the oligonucleotide Neutral liposome nanoparticle to incorporate readily into the lipi

  7. Slide 7: DNAbilize Technology: Compared to other Antisense

    Slide 7: DNAbilize Technology: Compared to other Antisense

    DNAbilize Technology ® Compared to other Antisense 1st Generation 2nd Generation DNAbilize® No toxicity Systemic Delivery Target Specific Effectiveness High Cellular Uptake Neutral charged stabilizing DNA backbone Unlike other antisense technologies that demonstrate toxicities and poor cellular deli

  8. Slide 8: DNAbilize Lead Target and Indications: Grb2 and Myeloid Leukemia

    Slide 8: DNAbilize Lead Target and Indications: Grb2 and Myeloid Leukemia

    DNAbilize® Lead Target and Indications: Grb2 and Myeloid Leukemia Prexigebersen is an antisense RNAi nanoparticle targeting Grb2 • Ideal target for myeloid leukemia because it shuts down the Ras pathway in receptor activated myeloid cells without exerting adverse effects on Ras signaling through oth

  9. Slide 9: Prexigebersen (BP1001): A Promising Treatment of Myeloid Leukemia

    Slide 9: Prexigebersen (BP1001): A Promising Treatment of Myeloid Leukemia

    Prexigebersen (BP1001): A Promising Treatment of Myeloid Leukemia Prexigebersen in combination with LDAC was well-tolerated and showed early anti-leukemic activity in nearly 50% of evaluable AML patients in Stage 1 of our Phase 2 studies PK: 30 hour half life in plasma 1 No adverse effects attribute

  10. Slide 10: Summary of Phase I Monotherapy Clinical Trial Results for Prexigebersen

    Slide 10: Summary of Phase I Monotherapy Clinical Trial Results for Prexigebersen

    Summary of Phase I Monotherapy Clinical Trial Results for Prexigebersen • N=39, AML, CML, & MDS Patients Refractory or Resistant to Current Therapies - Patients averaged 6 prior therapies • Dose escalating treatment cycle, 8 doses over 4 weeks, up to 90 mg/m2 • NO ADVERSE EVENTS/DRUG WAS WELL TOLERA

  11. Slide 11: Phase I Conclusions

    Slide 11: Phase I Conclusions

    Phase I Conclusions Results support that Grb2 is a potential therapeutic target for haematological malignancies • Favorable safety profile strongly suggests that BP1001 has a very different toxicity profile than other antisense oligonucleotide analogues, which have been associated with serum transam

  12. Slide 12: Stage 1 of the Phase II Efficacy Trial Design for AML

    Slide 12: Stage 1 of the Phase II Efficacy Trial Design for AML

    Stage 1 of the Phase II Efficacy Trial Design for AML Prexigebersen Combination Therapy • Treatment of de novo AML patients who are induction therapy ineligible and unfit for stem cell transplant • Efficacy trial conducted at 6 leading cancer centers in the U.S., including the MD Anderson Cancer Cen

  13. Slide 13: Safety Segment Phase II Prexigebersen

    Slide 13: Safety Segment Phase II Prexigebersen

    Safety Segment Phase II Prexigebersen + LDAC Combination Therapy Show Encouraging Results Relapsed/refractory AML patients - 3 evaluable patients per cohort, 2 cohorts, n=6 - Dose 60 mg/m2 and 90 mg/m2 respectively - Received drug 2x week for 4 weeks per treatment cycle Excellent Results - 3 patient

  14. Slide 14: Results of Stage 1 Interim Analysis

    Slide 14: Results of Stage 1 Interim Analysis

    Results of Stage 1 Interim Analysis Patient evaluation summary 5 Patients achieved CR (30%) Note: LDAC alone CR rate 7-13% +65% 6 Patients achieved stable disease (35%) 17 2 Stable disease patients had >50% bone marrow blasts reductions Of the evaluable patients 65% 1 CR patient was eligible for and

  15. Slide 15: Prexigebersen Phase 1b/2a CML Study

    Slide 15: Prexigebersen Phase 1b/2a CML Study

    Prexigebersen Phase 1b/2a CML Study Potential to treat the 33% of CML patients who are Gleevec resistant • Phase 1b prexigebersen + dasatinib study  Determine safety of the combination in accelerated and blast crisis CML patients  2 cohorts of 3 evaluable patients at 60 mg/m2 and 90 mg/m2  Compar

  16. Slide 16: Prexigebersen-A Phase 1 Study in Solid Tumors

    Slide 16: Prexigebersen-A Phase 1 Study in Solid Tumors

    Prexigebersen-A Phase 1 Study in Solid Tumors • Prexigebersen efficacy against ovarian tumors enhanced when combined with paclitaxel • Prexigebersen in combination with gemcitabine efficacious against pancreatic tumors • Clinical Plans  First - open a Phase 1/1b study of prexigebersen + paclitaxel

  17. Slide 17: BP1002 is an antisense RNAi nanoparticle targeting Bcl-2

    Slide 17: BP1002 is an antisense RNAi nanoparticle targeting Bcl-2

    BP1002 is an antisense RNAi nanoparticle targeting Bcl-2 Bcl-2 antisense oligo Oncogenic stress Cytotoxic Chemotherapy stimuli Radiation Mitochondria Anti-apoptotic BH3-only Bax Bak proteins Bcl-2 protein Apoptotic Cytochrome c proteins Apaf 1 Apoptotic Effector cell death caspases Caspase 9 By bloc

  18. Slide 18: BP1002 Summary

    Slide 18: BP1002 Summary

    BP1002 Summary • BP1002 decreased viability of lymphoma cells (11 of 15 lymphoma cell lines) • BP1002 extended survival of mice bearing lymphoma xenografts • Completed IND-enabling studies (pharmacokinetics, rodent toxicology), expected IND 3Q19 • Launch Phase 1 in lymphoma and CLL at MD Anderson, o

  19. Slide 19: BP1003 Targeting STAT3

    Slide 19: BP1003 Targeting STAT3

    BP1003 Targeting STAT3 • BP1003 has efficacy against non-small cell lung cancer, AML, and pancreatic cancer cells • BP1003 + gemcitabine combination is efficacious in pancreatic cancer-derived tumors • IND enabling studies during 2019 • Conduct a Phase 1 study of BP1003 in patients with refractory/m

  20. Slide 20: Experienced Leadership Team

    Slide 20: Experienced Leadership Team

    Experienced Leadership Team Officer and Director Medical consultant for Medimmune, Peter Nielsen since founding William Hahne, M.D. Lion Biotechnologies, Seattle Co-Founder, President, Company in 2007 Genetics, Aminex Therapeutics, Vice President of Chief Executive Officer Therakos, and Celgene Cell

  21. Slide 21: Scientific Advisory Board

    Slide 21: Scientific Advisory Board

    Scientific Advisory Board Jorge Cortes, M.D. • M.D. from la Facultad de Medicina, Universidad Nacional Autónoma de México • Jane and John Justin Distinguished Chair in Leukemia Research, Chief of the AML and CML sections, and Chairman Deputy Chair of the Department of Leukemia at The University of T

  22. Slide 22: IP and Financial Snapshot

    Slide 22: IP and Financial Snapshot

    IP and Financial Snapshot Intellectual Property • Original patents licensed from MD Anderson • New composition and methods of use patent issued covers DNAbilize® technology, solely owned by Bio-Path • Five additional patents pending Financial Snapshot • Ticker: NASDAQ: BPTH • Cash: $19.3 million as

  23. Slide 23: Bio-Path Holdings: Thank you

    Slide 23: Bio-Path Holdings: Thank you

    Bio-Path Holdings Thank you Bio-Path Holdings, Inc. 4710 Bellaire Blvd Suite 210 Bellaire, TX 77401 Web: www.biopathholdings.com Mail: partnering@biopathholdings.com Tel: (832) 742-1369 23

Source: Internet Archive copy of biopathholdings.com

More decks from Bio-Path Holdings, Inc.

All 11 Bio-Path decks